-transparent.png){kind=logo}
This study on serum ferritin levels in urinary iron excretion after 12h subcutaneous infusion of desferrioxamine in 10 thalassemia intermedia patients shows that even nontransfusion-dependent patients may have positive iron balance resulting in iron overload from 5 years of age. However, the iron overload found in these patients appears to be much lower than in age matched patients with transfusion-dependent thalassemia major. Iron overload increases with advancing age, as shown by increasing serum ferritin levels and desferrioxamine-induced urinary iron elimination. After a six month trial of 12h continuous subcutaneous desferrioxamine administration there was a significant decline in serum ferritin levels. From this study it seems that iron chelation is indicated in thalassemia intermedia patients over 5 years of age in order to prevent iron accumulation. However, the appropriate treatment schedule should be tailored to the individual needs of each patients, established by close monitoring of serum ferritin levels and desferrioxamine-induced urinary iron elimination.
P Cossu, and
C Toccafondi, and
F Vardeu, and
G Sanna, and
F Frau, and
R Lobrano, and
G Cornacchia, and
A Nucaro, and
F Bertolino, and
A Loi, and
S De Virgiliis, and
A Cao
April 2004,
Haematologica,
P Cossu, and
C Toccafondi, and
F Vardeu, and
G Sanna, and
F Frau, and
R Lobrano, and
G Cornacchia, and
A Nucaro, and
F Bertolino, and
A Loi, and
S De Virgiliis, and
A Cao
January 1988,
Birth defects original article series,
P Cossu, and
C Toccafondi, and
F Vardeu, and
G Sanna, and
F Frau, and
R Lobrano, and
G Cornacchia, and
A Nucaro, and
F Bertolino, and
A Loi, and
S De Virgiliis, and
A Cao
January 2019,
Metal ions in life sciences,
P Cossu, and
C Toccafondi, and
F Vardeu, and
G Sanna, and
F Frau, and
R Lobrano, and
G Cornacchia, and
A Nucaro, and
F Bertolino, and
A Loi, and
S De Virgiliis, and
A Cao
March 1990,
Indian pediatrics,
P Cossu, and
C Toccafondi, and
F Vardeu, and
G Sanna, and
F Frau, and
R Lobrano, and
G Cornacchia, and
A Nucaro, and
F Bertolino, and
A Loi, and
S De Virgiliis, and
A Cao
October 1995,
Seminars in hematology,
P Cossu, and
C Toccafondi, and
F Vardeu, and
G Sanna, and
F Frau, and
R Lobrano, and
G Cornacchia, and
A Nucaro, and
F Bertolino, and
A Loi, and
S De Virgiliis, and
A Cao
December 2017,
International journal of molecular sciences,
P Cossu, and
C Toccafondi, and
F Vardeu, and
G Sanna, and
F Frau, and
R Lobrano, and
G Cornacchia, and
A Nucaro, and
F Bertolino, and
A Loi, and
S De Virgiliis, and
A Cao
November 1978,
Israel journal of medical sciences,
P Cossu, and
C Toccafondi, and
F Vardeu, and
G Sanna, and
F Frau, and
R Lobrano, and
G Cornacchia, and
A Nucaro, and
F Bertolino, and
A Loi, and
S De Virgiliis, and
A Cao
May 2006,
Annals of hematology,
P Cossu, and
C Toccafondi, and
F Vardeu, and
G Sanna, and
F Frau, and
R Lobrano, and
G Cornacchia, and
A Nucaro, and
F Bertolino, and
A Loi, and
S De Virgiliis, and
A Cao
December 2009,
British journal of haematology,
P Cossu, and
C Toccafondi, and
F Vardeu, and
G Sanna, and
F Frau, and
R Lobrano, and
G Cornacchia, and
A Nucaro, and
F Bertolino, and
A Loi, and
S De Virgiliis, and
A Cao
August 2014,
Hematology/oncology clinics of North America,
